Claudin 18.2在胃癌靶向免疫治疗中的新突破与展望  

Emerging breakthroughs and future prospects of Claudin18.2 in targeted therapy and immunotherapy for gastric cancer

作　　者：姜家钰 方振 郑可心 蔡宝珊 赵育龙 刘兆栋 靖昌庆 李乐平 商亮 Jiang Jiayu;Fang Zhen;Zheng Kexin;Cai Baoshan;Zhao Yulong;Liu Zhaodong;Jing Changqing;Li Leping;Shang Liang(Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China;Shandong Provincial Hospital,Shandong University,Jinan 250021,China)

机构地区：[1]山东第一医科大学附属省立医院胃肠外科,济南250021 [2]山东大学山东省立医院胃肠外科,济南250021

出　　处：《中华消化外科杂志》2025年第3期343-349,共7页Chinese Journal of Digestive Surgery

基　　金：国家自然科学基金(82203854,82372772);山东省泰山学者计划专项基金(ts20190978,tsqn202408363)。

摘　　要：胃癌作为一种高度恶性肿瘤,近年来全球发病率持续上升。Claudin 18.2是一种在胃癌中高度特异性表达的蛋白,成为胃癌治疗研究热点。Claudin 18.2在胃癌细胞中的过表达及其独特的位置暴露现象,为胃癌靶向和免疫治疗提供了新的突破口。针对Claudin 18.2的治疗方法在临床试验中已取得初步成果,主要包括单克隆抗体和嵌合抗原受体T细胞疗法等。笔者围绕Claudin 18.2的生物学特性、作用机制、临床研究进展以及未来的治疗前景与挑战进行深入阐述。Gastric cancer,a highly malignant tumor,has seen a persistent rise in global incidence in recent years.Claudin 18.2,a protein with highly specific expression in gastric cancer,has emerged as a prominent research target in therapeutic development.The overexpression of Claudin 18.2 in gastric cancer cells and its abnormal surface exposure provide novel opportunities for targeted and immunotherapeutic interventions.Therapeutic approaches targeting Claudin 18.2 have shown promising initial results in clinical trials,primarily including monoclonal antibodies and chimeric antigen receptor T-cell therapies.The authors systematically summarize the biological characteristics,mechanism of action,clinical research progress,and future treatment prospects and challenges of Claudin 18.2.

关 键 词：胃肿瘤 Claudin 18.2 靶向治疗 免疫治疗 生物标志物 

分 类 号：R735.2[医药卫生—肿瘤]